Navigation Links
Ampio Pharmaceuticals Provides Clinical Updates
Date:6/3/2013

GREENWOOD VILLAGE, Colo., June 3, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) today announced an update on its clinical progress for AmpionTM, OptinaTM, the sexual dysfunction portfolio, and Luoxis Diagnostics, Inc.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

Ampion

In the SPRING trial, Ampion is being evaluated for its effect on reducing pain in osteoarthritis of the knee, measured by the WOMAC scale, as a single intra-articular injection into the knee in 4 milliliter (mL) and 10 milliliter (mL) volumes as compared to placebo at twelve weeks. The study treated in excess of the targeted 320 patient goal in less than four weeks. This was designed as a run-in to a Phase III pivotal trial, which Ampio will initiate once the optimal volume is determined and the proposed pivotal trial is properly powered to achieve its scientific objectives. By June 7th, all patients in the SPRING trial will have received the three follow-up phone calls and the six (6) week exam that followed the baseline exam at time of dosing. Clinical results from the completed trial, which includes additional follow-up calls and a final exam, will be made available in the third quarter of 2013.  These results will be the basis for corporate strategy and business negotiations going forward.

Optina

Optina (danazol) is being tested in a 505(b)(2) trial to treat diabetic macular edema (DME).  This may become the pivotal trial as a portion of 505(b)(2) drugs receive FDA registration based on a single clinical trial.

The randomized, placebo-controlled, double-masked, multicenter United States trial is expected to enroll approximately 450 patients. The primary endpoint is impro
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Synergy Health Wins Practice Green Health Champion for Change Award
2. Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee
3. Former NBA Champion John Salley Partners With Watertree Health To Promote Free Prescription Discount Card
4. Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
5. Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
6. Americans United for Life Celebrates Win for Illinois Conscience Rights in Case AUL Championed Since 2005
7. Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting
8. Novation Champions Reusable Packaging for Sustainability in Healthcare
9. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
10. Champions Oncology Reports Financial Results for the Quarter Ended July 31, 2012
11. Terso Solutions partners with Champion Medical Technologies to offer fully automated tracking of Tissue and Implantable Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... 2, 2011 Reportlinker.com announces ... report is available in its ... Cardiology Devices: World Market Prospects ... http://www.reportlinker.com/p0663863/Interventional-Cardiology-Devices-World-Market-Prospects-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine Our ...
... 2, 2011 Syndax Pharmaceuticals, Inc ., a ... in a subset of patients from ENCORE 301, a ... entinostat in advanced breast cancer patients, will be presented ... for Cancer Research (AACR) Molecular Targets and Cancer Therapeutics ...
Cached Medicine Technology:Interventional Cardiology Devices: World Market Prospects 2011-2021 2Interventional Cardiology Devices: World Market Prospects 2011-2021 3Interventional Cardiology Devices: World Market Prospects 2011-2021 4Interventional Cardiology Devices: World Market Prospects 2011-2021 5Interventional Cardiology Devices: World Market Prospects 2011-2021 6Interventional Cardiology Devices: World Market Prospects 2011-2021 7Interventional Cardiology Devices: World Market Prospects 2011-2021 8Interventional Cardiology Devices: World Market Prospects 2011-2021 9Interventional Cardiology Devices: World Market Prospects 2011-2021 10Interventional Cardiology Devices: World Market Prospects 2011-2021 11Interventional Cardiology Devices: World Market Prospects 2011-2021 12Interventional Cardiology Devices: World Market Prospects 2011-2021 13Interventional Cardiology Devices: World Market Prospects 2011-2021 14Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011 2Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011 3
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... released a new blog post explaining the importance of keeping a ... of an auto insurance policy . , Clients who driver ... their vehicle insurance policies. The safety a vehicle offers from its ... of this, drivers should always carry a first aid kit in ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... - Adjusted Diluted EPS (1) was $0.42 -- Annual Guidance Narrowed to $2.05 to $2.18 Adjusted Diluted ... West Pharmaceutical Services, Inc. (NYSE: WST ) today announced its results for the first quarter ... Three Months Ended, ... ...
... April 30 Quigley Pharma Inc., www.quigleyco.com ... Corporation (Nasdaq: QGLY ) announced today that ... of diabetic peripheral neuropathy, demonstrated a significant improvement in ... the group treated with QR333. The compound was ...
... PARK CITY, Utah, April 30 Nutraceutical International Corporation (Nasdaq: ... 2009 second quarter ended March 31, 2009. Net sales ... to $44.4 million for the same quarter of fiscal 2008.Primarily ... recession and the related turmoil in the equity markets, there ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... the following 2009 first quarter results: , ... revenues of $288.9 million for the quarter ended March 29, ... $77.8 million from its CareCentrix business unit, for the quarter ...
... April 3 In conjunction with its first quarter 2009 earnings ... 2009), Covance Inc. (NYSE: CVD ) is pleased to ... will be broadcast live over the Internet on Thursday, April 30, ... First Quarter 2009 Earnings Webcast and Slide Presentation, ...
... increases 9 percent to $24.9 billion- GAAP earnings from ... decrease 10 percent to $350 million on a non-GAAP ... decline 15 percent to $0.87 and decrease 10 percent ... Cardinal Health, a global provider of products and ...
Cached Medicine News:Health News:West Announces First Quarter 2009 Results 2Health News:West Announces First Quarter 2009 Results 3Health News:West Announces First Quarter 2009 Results 4Health News:West Announces First Quarter 2009 Results 5Health News:West Announces First Quarter 2009 Results 6Health News:West Announces First Quarter 2009 Results 7Health News:West Announces First Quarter 2009 Results 8Health News:West Announces First Quarter 2009 Results 9Health News:West Announces First Quarter 2009 Results 10Health News:West Announces First Quarter 2009 Results 11Health News:West Announces First Quarter 2009 Results 12Health News:West Announces First Quarter 2009 Results 13Health News:West Announces First Quarter 2009 Results 14Health News:West Announces First Quarter 2009 Results 15Health News:West Announces First Quarter 2009 Results 16Health News:West Announces First Quarter 2009 Results 17Health News:West Announces First Quarter 2009 Results 18Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 2Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 3Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 4Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 2Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 3Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 4Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 5Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 6Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 7Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 8Health News:Gentiva Reports First Quarter 2009 Results 2Health News:Gentiva Reports First Quarter 2009 Results 3Health News:Gentiva Reports First Quarter 2009 Results 4Health News:Gentiva Reports First Quarter 2009 Results 5Health News:Gentiva Reports First Quarter 2009 Results 6Health News:Gentiva Reports First Quarter 2009 Results 7Health News:Gentiva Reports First Quarter 2009 Results 8Health News:Gentiva Reports First Quarter 2009 Results 9
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: